CPT code 96372 is the code you report when a physician, or clinical staff under the right supervision, gives a therapeutic, prophylactic, or diagnostic injection under the skin or into a muscle. The AMA descriptor reads: "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular." The code pays for giving the shot. The drug goes on its own claim line with a HCPCS code, usually a J-code.
In our experience, injection denials usually trace to the lines around 96372: a modifier on the wrong line, a 99211 that Medicare won't pay, or a drug code with the wrong units. This guide covers each of those, plus what Medicare pays in 2026 and what changes on January 1, 2027. The main rules link to the CMS, AMA, Medicare contractor, or payer source they come from.
CPT 96372 at a glance
|
Question |
Answer |
|---|---|
|
Code description (AMA) |
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular |
|
CMS short descriptor |
THER/PROPH/DIAG INJ SC/IM |
|
Code type |
Category I CPT code, which is also HCPCS Level I |
|
What it covers |
Giving one subcutaneous (SC) or intramuscular (IM) injection; the drug is billed separately |
|
Units |
One per injection |
|
Office (POS 11) |
Reported by the physician or supervising practitioner |
|
Hospital outpatient department or ED |
Not reported by the physician; the hospital reports it (NCCI Policy Manual, Ch. XI, §B.7) |
|
Billed with 99211 (Medicare and NCCI) |
Not separately payable (NCCI Ch. XI, §B.8) |
|
Billed with 99212 to 99215 (Medicare and NCCI) |
Payable when the visit is significant and separately identifiable; modifier 25 goes on the E/M, not on 96372 |
|
Vaccines |
Not 96372; use 90460 to 90474, 90480, or G0008 to G0010 |
|
Chemotherapy and other highly complex drugs given SC or IM |
Not 96372; use 96401 or 96402 |
|
Global period |
XXX (the global surgery rules don't apply) |
|
Medicare 2026 national payment, non-facility |
$15.36 (0.46 total RVUs at the $33.4009 conversion factor) |
|
Medicare 2027 |
Conversion factor drops to $32.63 (non-qualifying APM participants) |
What is CPT code 96372?
CPT code 96372 is an administration code for a therapeutic, prophylactic, or diagnostic injection given subcutaneously or intramuscularly. It sits in the CPT drug administration family (96360 to 96379), which covers hydration and non-chemotherapy injections and infusions. As a Category I CPT procedure code, it's also a HCPCS Level I code, so "HCPCS 96372" and "procedure code 96372" mean the same thing.
The AMA's own clinical example is a 70-year-old patient with pneumonia who gets an IM antibiotic such as ceftriaxone. That's the typical 96372 visit: a drug the office stocks, given by needle, with the drug billed on its own line.
CPT 96372 code description
The CPT 96372 code description is "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular." On fee schedules and remittances you'll also see the CMS short descriptor, "THER/PROPH/DIAG INJ SC/IM," and the medium descriptor, "Therapeutic prophylactic/dx injection subq/im." All three describe the same code.
In plain terms, you bill 96372 when someone in your office gives a qualifying drug by needle under the skin or into a muscle. The code pays for that work. The drug itself is never part of 96372; it goes on its own line with the HCPCS code for that product.
What does "therapeutic, prophylactic, or diagnostic" mean?
In the CPT 96372 descriptor, these three words describe why the injection is given. A therapeutic injection treats an active problem, such as IM ceftriaxone for pneumonia or ketorolac for acute pain, which is why searches for a "therapeutic injection CPT code" usually land on 96372. A prophylactic injection prevents something, such as a medroxyprogesterone contraceptive injection.
Diagnostic SC or IM injections are uncommon in office practice, but the code covers them too. The purpose doesn't change the code; the route does.
Is CPT 96372 an administration code?
Yes. CPT 96372 is an administration code. It covers the clinical work of giving the injection, while the drug is billed separately with its HCPCS code. CPT's drug administration guidelines also treat routine supplies such as syringes as part of the service, so they aren't billed on their own lines.
What is the CPT code for an IM or subcutaneous injection?
The CPT code for an intramuscular (IM) or subcutaneous (SC) injection of a non-vaccine, non-chemotherapy drug is 96372. The route doesn't change the code. What the route does change is the documentation: the chart has to say which route was used and where the injection went, and the drug goes on its own HCPCS line.
|
Feature |
Subcutaneous (SC) |
Intramuscular (IM) |
|---|---|---|
|
Where the drug goes |
Fatty tissue under the skin |
Into the muscle |
|
Common sites |
Abdomen, upper arm, thigh |
Deltoid, gluteal, vastus lateralis |
|
Office examples |
Denosumab, inclisiran |
Ceftriaxone, ketorolac, testosterone cypionate, B12 |
|
CPT code |
96372 |
96372 |
What changed for CPT 96372 in 2027
The 96372 code itself isn't changing for 2027 based on what's been published, but Medicare payment and editing around it are. These changes are confirmed as of November 9, 2026.
- The CY 2027 Physician Fee Schedule final rule, released November 4, 2026, sets the conversion factor at $32.63 for clinicians who aren't qualifying APM participants (down 2.31%) and $32.95 for qualifying participants (down 1.83%), effective January 1, 2027. The one-year 2.5% increase from 2026 expires. Congress has changed the conversion factor after final rules before, so these hold unless new legislation passes.
- CMS is phasing out its indirect practice cost index over two years and will allocate indirect practice expense based on both work and clinical labor RVUs. Practice expense is most of 96372's value, so check its final 2027 RVUs, which CMS published in the final rule addenda.
- When an office or outpatient E/M is billed with modifier 25 on the same day as a procedure with a 0-day global period, the highest-valued service is paid in full and the other at 80%. 96372 carries an XXX global indicator, not a 0-day global, so the rule as written shouldn't reach an E/M plus injection visit.
- HCPCS add-on code G2211 is replaced by modifier B1 on the E/M line in 2027.
- CMS issued NCCI PTP version 33.0, effective January 1, 2027. Version 32.3, effective October 1, 2026 under transmittal R13829CP, applies until then.
- The AMA's CPT 2027 release adds 299 codes, revises 74, and deletes 80. The published highlights don't include the drug administration codes.
When to use CPT code 96372 and when not to
Use 96372 when a non-vaccine, non-chemotherapy drug is injected SC or IM in a setting where the practitioner bills for the administration, which in practice means the office. Hospitals report the same code on their own facility claims.
What is CPT code 96372 used for?
CPT code 96372 is used for the in-office SC or IM administration of drugs such as antibiotics, vitamin B12, testosterone, ketorolac, extended-release naltrexone, ondansetron, medroxyprogesterone, denosumab, and inclisiran. The J-code and diagnosis code for each one are in the reference table further down. In every case, the administration goes on the 96372 line and the drug goes on its own line.
What is included in CPT code 96372?
CPT code 96372 includes the work of preparing and giving one SC or IM injection, along with the routine supplies used to give it. These fall outside it and are billed, or not billed, on their own terms:
- The drug, billed with its HCPCS code
- A significant, separately identifiable E/M visit, billed with modifier 25
- Vaccine administration, which has its own codes
- A second, separate injection, billed as another unit of 96372
One injection is one unit. Noridian, for example, counts a single dose that has to be split across two syringes as one 96372 in its drug administration guidance.
When not to use CPT code 96372
Don't use CPT 96372 for vaccines, chemotherapy, IV push or infusion, joint injections, or injections given in a hospital outpatient department, which the hospital reports. This table lists the code to use instead.
|
Situation |
Use instead |
Source |
|---|---|---|
|
Vaccine or toxoid |
90460 to 90474, 90480; Medicare flu, pneumococcal, and hepatitis B: G0008, G0009, G0010 |
NCCI Ch. XI, §B.13 to B.15 |
|
Chemotherapy or other highly complex drug given SC or IM |
96401 (non-hormonal) or 96402 (hormonal antineoplastic) |
CPT descriptors; NCCI Ch. XI, §B.1 |
|
Intra-arterial injection |
96373 |
CPT |
|
IV push |
96374, 96375, 96376 |
CPT |
|
IV infusion or hydration |
96360 to 96368 |
CPT |
|
Joint or bursa injection |
20600 to 20611 |
CPT |
|
Trigger point injection |
20552, 20553 |
CPT |
|
Allergen immunotherapy |
95115, 95117 |
CPT |
|
Injection given in a hospital outpatient department or ED |
Physician doesn't report it; the hospital does |
NCCI Ch. XI, §B.7 |
|
Drug the patient injects at home |
Nothing to bill for administration |
N/A |
CPT 96372 vs. other injection codes
CPT 96372 is one of several administration codes that look alike on a fee ticket. The difference is usually the route or the kind of drug.
|
Code |
What it reports |
Route |
|---|---|---|
|
96372 |
Therapeutic, prophylactic, or diagnostic injection |
SC or IM |
|
96373 |
Therapeutic, prophylactic, or diagnostic injection |
Intra-arterial |
|
96374 |
IV push, single or initial drug |
IV |
|
96375 |
IV push, each additional sequential new drug |
IV |
|
96401 |
Chemotherapy administration, non-hormonal antineoplastic |
SC or IM |
|
96402 |
Chemotherapy administration, hormonal antineoplastic |
SC or IM |
|
90471 |
Immunization administration, first vaccine |
IM, SC, or intradermal |
|
G0008 |
Medicare influenza vaccine administration |
IM |
|
20610 |
Arthrocentesis, aspiration, or injection, major joint or bursa |
Intra-articular |
CPT 96372 vs. 90471: which one do you bill?
CPT 96372 is for non-vaccine SC or IM injections, and 90471 is for vaccine and toxoid administration, so the drug decides the code. B12, testosterone, and ketorolac go on 96372. Flu, Tdap, and pneumococcal vaccines go on 90471 (and 90472 for each additional vaccine), or on G0008 to G0010 for those Medicare vaccines.
When a patient gets a flu shot and a B12 injection at the same visit, both administration codes are reportable: 90471 (or G0008 for Medicare) with the vaccine product code, and 96372 with J3420. Don't add modifier 59 to 96372 out of habit. Check the current NCCI PTP table for that pair first. Our 90471 billing guide covers the vaccine side.
Is CPT 96372 used for chemotherapy?
No. Chemotherapy and other highly complex drugs given SC or IM are reported with 96401 or 96402, not 96372. Leuprolide for prostate cancer is the classic trap: it's an IM or SC injection, but as a hormonal antineoplastic it goes on 96402, which Palmetto GBA's billing article A59160 supports. MACs haven't always agreed on this, so check yours. Our guide to chemotherapy administration codes covers 96401 through 96549.
CPT 96372 vs. 20610: when to use each code
CPT 96372 reports an SC or IM injection, while 20610 reports an injection into a major joint or bursa, such as a steroid into the knee. Both can be billed at one visit when they treat separate problems, each with its own drug line and diagnosis. A steroid into the knee is 20610; ketorolac into the deltoid is 96372.
If the current NCCI PTP table pairs the two codes, the modifier usually goes on the column 2 code, and only when the documentation shows a separate site and purpose. Modifier XS (separate structure) is often more precise than 59 here, as CMS explains in its modifier 59 and X{EPSU} fact sheet.
Same-day billing scenarios for CPT 96372
Most questions about 96372 are really questions about what else was billed that day. This table answers the common ones for Medicare and for payers that follow NCCI. Commercial payers can differ, as the payer section below shows.
|
What happened |
What to bill |
Modifier and where it goes |
Source |
|---|---|---|---|
|
Patient came in only for the injection |
96372 + drug code |
None |
NCCI Ch. XI, §B.8 |
|
Nurse visit with the injection, billed as 99211 |
96372 + drug code; drop 99211 |
Modifier 25 doesn't make 99211 payable |
NCCI Ch. XI, §B.8 |
|
Provider evaluated a separate problem and gave an injection |
99212 to 99215 + 96372 + drug code |
25 on the E/M; nothing on 96372 |
NCCI Ch. XI, §B.8 |
|
Provider evaluated a problem and gave an injection for the same problem |
99212 to 99215 + 96372 + drug code, if the visit is significant on its own |
25 on the E/M; a different diagnosis isn't required |
CPT modifier 25 definition |
|
Injection given in a hospital outpatient department or ED |
Physician bills the E/M only; the hospital bills 96372 |
None for the physician |
NCCI Ch. XI, §B.7 |
|
Injection plus a vaccine |
96372 + drug code; vaccine admin code + vaccine product code |
Only if the current PTP table pairs them |
NCCI Ch. XI, §B.13 |
|
Injection plus a joint injection |
20610 + 96372, each with its drug code |
Usually on the column 2 code, if an edit applies |
NCCI PTP table |
|
Two different drugs, two separate injections |
96372 for each injection + both drug codes |
Some payers want 59 on the second line |
Payer policy |
|
One dose split across two syringes |
96372 once + the drug code |
None |
Noridian |
|
Patient brought their own drug |
96372 + drug line per the payer's rules |
None |
Payer policy |
CPT 96372 modifier guide: 25, 59, X modifiers, 76, 77, JW, and JZ
In our experience, modifier mistakes are among the most common reasons injection claims come back, and most of them put the right modifier on the wrong line. This matrix shows where each one goes.
|
Situation |
Modifier |
Goes on |
Example |
|---|---|---|---|
|
Injection only |
None |
N/A |
96372 |
|
Separately identifiable E/M the same day |
25 |
The E/M line |
99213-25, 96372 |
|
A PTP edit pairs 96372 with another procedure, and the services were distinct |
59 or XE, XP, XS, XU |
Usually the column 2 code |
96372-XS with 20610 |
|
Payer asks for a modifier on second and later injections |
59 (per payer) |
The second 96372 line |
96372, 96372-59 |
|
Same procedure repeated later the same day |
76 or 77, if the payer accepts them |
The repeat line |
Payer-specific |
|
Drug from a single-dose container, part discarded (Medicare) |
JW |
The drug line, for the discarded amount |
J-code-JW |
|
Drug from a single-dose container, nothing discarded (Medicare) |
JZ |
The drug line |
J-code-JZ |
Does CPT 96372 need a modifier?
Usually not. CPT 96372 billed on its own takes no modifier. When the provider also performs a significant, separately identifiable E/M visit, modifier 25 goes on the E/M code, not on 96372. A modifier on 96372 itself only comes up when an NCCI or payer edit pairs it with another procedure and the services were truly separate, or when a payer's policy asks for one on the second injection.
Does 96372 need a modifier when billed with 99214?
No modifier goes on 96372. Put modifier 25 on 99214 when the visit is significant and separately identifiable from the injection. The NCCI Policy Manual (Ch. XI, §B.8) says 99202 to 99205 and 99212 to 99215 are separately reportable with drug administration codes when modifier 25 is used. The same logic applies to 99212, 99213, and 99215.
Modifier 25 and CPT 96372: when it applies
Modifier 25 belongs on the E/M code, and only when the provider did more than decide to give the shot and check the patient afterward. The note should show what was evaluated, what was decided, and why the visit stands on its own. The diagnosis can match the injection's diagnosis; CPT's definition of modifier 25 doesn't require a different one.
This is a clean office claim for a patient seen for new right shoulder pain and treated with IM ketorolac:
|
Line |
Code |
Diagnosis |
What it reports |
|---|---|---|---|
|
1 |
99213-25 |
M25.511 |
Office visit: history, exam, and plan for the shoulder |
|
2 |
96372 |
M25.511 |
IM injection |
|
3 |
J1885 × 2 |
M25.511 |
Ketorolac 30 mg (J1885 is per 15 mg) |
No modifier goes on line 2. Older guidance that adds 59 to 96372 in this situation doesn't match NCCI, and it's the kind of pattern auditors notice.
Modifier 25 can't rescue 99211 for Medicare. The NCCI manual says the drug administration codes 96360 to 96379 were valued to include the work and practice expense of 99211, so 99211 isn't separately reportable with 96372, with or without modifier 25.
Some commercial payers set their own rule; BCBS Texas, for example, tells providers to use 99211 instead of 96372 when an injection is given without direct supervision. Our 99211 billing guide covers when a nurse visit can stand alone.
Modifier 59 and CPT 96372: when and how to use it
Modifier 59 goes on CPT 96372 only when an NCCI PTP edit pairs it with another procedure, such as 20610, and the record shows a separate site or purpose. CMS prefers the more specific X modifiers where one fits: XS for a separate structure, XE for a separate encounter, XP for a separate practitioner, and XU for an unusual non-overlapping service.
Modifier 59 doesn't belong on an E/M code, and it doesn't belong on 96372 just because an E/M was billed the same day. Some commercial payers do ask for 59 on the second and later 96372 lines; BCBS Texas, for example, says so in its injection and infusion policy. Our modifier 59 guide goes deeper on PTP edits.
JW and JZ modifiers: drug waste reporting for Medicare
JW and JZ go on the drug line, never on 96372. They apply to separately payable Part B drugs from a single-dose container or single-use package. JW reports the amount discarded, and JZ says nothing was discarded. Multi-dose vials don't take either modifier.
Medicare has required JZ since July 1, 2023, and since October 1, 2023, claims missing a required JW or JZ can be returned as unprocessable, per the CMS JW/JZ FAQ. JW amounts also feed the discarded drug refund program, which bills manufacturers when waste generally runs above 10% of allowed charges. A B12 dose drawn from a multi-dose vial takes neither modifier.
|
A modifier on the wrong line can cost you the whole visit MedSole's claim submission team checks every injection claim before it goes out. We confirm modifier 25 is on the E/M and nothing extra is on 96372, check drug units against the J-code, and add the NDC wherever the payer asks for it. |
CPT 96372 billing guidelines (CMS and NCCI)
A clean 96372 claim needs the administration line, the drug line, a diagnosis that supports the drug, the right place of service, and the right modifiers. We work through these nine steps on every injection claim.
How to bill CPT code 96372 correctly
- Check coverage and authorization for the drug before the visit. High-cost drugs, biologics, and GLP-1s often need prior authorization, and a missing authorization usually takes down both lines.
- Document the order, drug name, dose, route, injection site, date and time, who gave it, and how the patient tolerated it. Lot number and expiration date are good practice, and some payers ask for them.
- Meet the supervision rules. For Medicare incident-to billing, the supervising practitioner has to provide direct supervision. Since January 1, 2026, real-time audio and video (not audio-only) can meet that for incident-to services, except services with a 010 or 090 global period, per CMS MLN MM14315. State scope-of-practice rules and payer policies still apply.
- Pick the drug's HCPCS code and calculate units from its dosage descriptor. J1885 is per 15 mg, so 30 mg of ketorolac is two units.
- Add the NDC where the payer requires it (see the NDC section below).
- Apply modifiers using the matrix above.
- Check the NCCI PTP edits and the practitioner MUE for 96372 on the date of service. CMS updates both every quarter.
- Set the place of service: POS 11 for the office. For a hospital outpatient department or ED, the physician doesn't bill 96372.
- Scrub the claim for missing units, NDC formatting, and modifier placement, then submit.
Can CPT code 96372 be billed alone?
Yes. CPT code 96372 can be billed alone when the injection is the only service at the visit, with the drug code on its own line. That's the normal claim for a scheduled B12, testosterone, or medroxyprogesterone visit. For Medicare and NCCI-based payers, don't add 99211 to it, because 99211 isn't payable with 96372.
Can CPT code 96372 be billed twice on the same day?
Yes, when two separate injections are given. Report 96372 once for each injection, with a drug line for each drug. Check the current practitioner MUE for 96372 before billing several units, since CMS denies units over the MUE. Then follow the payer's format: some want units on one line, others want separate lines with 59 on the second.
Patient-supplied medication and CPT 96372
When the patient brings the drug, the practice still bills 96372 for giving it but doesn't bill for the drug. Payers handle the drug line differently. BCBS Texas asks for the drug code on its own line with a $0.00 charge when no E/M is billed, so the claim shows what was given. Others want the drug name and dose in item 19 of the CMS-1500. Check the payer's policy before the first claim.
What revenue code should be billed with 96372?
On a UB-04 hospital claim, the drug with a HCPCS code goes under revenue code 0636 (drugs requiring detailed coding), and 96372 goes under the revenue code for the department that gave the injection, such as 045x for the emergency room. CMS doesn't assign HCPCS codes to revenue codes; the Medicare Claims Processing Manual (Ch. 4, §20.5) leaves that to each hospital's chargemaster. Physician claims on the CMS-1500 don't use revenue codes.
CPT 96372 reimbursement, RVUs, and coverage
Medicare pays a modest amount for 96372 itself; the drug line is usually where the money is. Both lines need to be right for the claim to pay in full.
Is CPT code 96372 covered by Medicare?
Yes. Medicare Part B covers 96372 when the drug is covered under Part B and medically necessary, the injection is given where the practitioner can bill for it, and supervision rules are met. Drugs that patients usually inject themselves are generally excluded from Part B; each MAC publishes a self-administered drug (SAD) exclusion list. Coverage for specific drugs can also depend on your MAC's LCDs and billing articles.
What does Medicare pay for CPT code 96372?
For 2026, Medicare's national non-facility payment for 96372 is $15.36 before locality adjustment. That's 0.46 total RVUs (0.17 work, 0.28 practice expense, 0.01 malpractice) times the 2026 conversion factor of $33.4009. Some fee tables also show a facility amount, but under NCCI §B.7 the physician doesn't report 96372 for injections in a hospital outpatient department or ED, so the non-facility rate is the one that matters for office billing.
|
Component |
2026 value |
|---|---|
|
Work RVU |
0.17 |
|
Practice expense RVU (non-facility) |
0.28 |
|
Malpractice RVU |
0.01 |
|
Total RVUs |
0.46 |
|
Conversion factor (non-QP) |
$33.4009 |
|
National non-facility payment |
$15.36 |
For 2027, the conversion factor drops to $32.63 for non-qualifying APM participants and $32.95 for qualifying participants. Your local rate depends on your locality's GPCI adjustment; the CMS PFS look-up tool shows it for each year.
The drug line is paid separately. For most separately payable Part B drugs given in the office, Medicare pays 106% of the Average Sales Price (ASP plus 6%) from the quarterly ASP file, before the 2% sequestration cut. Qualifying biosimilars are paid at ASP plus 8%.
Is CPT code 96372 covered by Medicaid?
State Medicaid programs generally cover injection administration, but rates and rules vary by state and by managed care plan. Third-party estimates from PayerPrice put the median Medicaid rate for 96372 at $12.64 across 42 state programs. Medicaid also requires an NDC on physician-administered drug claims, so a missing NDC is a common Medicaid denial even when Medicare pays the same claim.
Commercial rates depend on your contract. As a rough benchmark, PayerPrice's estimates (data as of October 2026) show averages of $21.47 for BCBS/Anthem, $20.37 for UnitedHealthcare, $22.95 for Aetna, and $35.24 for Cigna. PayerPrice doesn't publish its method for these figures, so treat them as a starting point for contract talks, not a standard.
ICD-10 codes and J-codes for CPT 96372
The diagnosis on the 96372 line should be the condition the drug treats or prevents, and it should match the drug's coverage criteria. This table shows common pairings. The ICD-10-CM codes were checked against the FY 2027 code set, effective October 1, 2026.
|
Drug |
Brand example |
HCPCS code |
Example ICD-10-CM codes |
|---|---|---|---|
|
Ceftriaxone |
Rocephin |
J0696 (per 250 mg) |
J18.9 (pneumonia, unspecified organism) |
|
Cyanocobalamin |
Vitamin B12 |
J3420 (up to 1,000 mcg) |
D51.0, D51.8, D51.9, E53.8 |
|
Testosterone cypionate |
Depo-Testosterone |
J1071 (1 mg) |
E29.1 (testicular hypofunction) |
|
Testosterone enanthate |
Generic |
J3121 (1 mg) |
E29.1 |
|
Ketorolac |
Toradol |
J1885 (per 15 mg) |
M54.50 (low back pain, unspecified), M25.511 (right shoulder pain) |
|
Methylprednisolone acetate |
Depo-Medrol |
J1010 (1 mg) |
Per indication |
|
Naltrexone, extended-release |
Vivitrol |
J2315 (1 mg) |
F11.20, F10.20 |
|
Ondansetron |
Zofran |
J2405 (per 1 mg) |
R11.0 (nausea) |
|
Medroxyprogesterone |
Depo-Provera |
J1050 (1 mg) |
Z30.013 (initial), Z30.42 (surveillance) |
|
Denosumab |
Prolia |
J0897 (1 mg) |
M81.0 (age-related osteoporosis) |
|
Inclisiran |
Leqvio |
J1306 (1 mg) |
E78.00 and other hyperlipidemia codes per label |
|
Semaglutide or tirzepatide (where a payer covers in-office use) |
Ozempic, Mounjaro, Wegovy, Zepbound |
J3490 or J3590 with NDC, per payer |
E11.9; E66.811 to E66.813 with a Z68 BMI code |
Methylprednisolone acetate moved to J1010 on April 1, 2024, when J1020, J1030, and J1040 were deleted, so 80 mg is now 80 units. Denosumab biosimilars have their own Q-codes (Q5136 and others), so match the code to the exact product given.
ICD-10 codes most commonly paired with CPT 96372
There's no single diagnosis code for 96372. The code depends on the drug and the reason it was given, and it has to support that drug's coverage rules. Two mistakes come up often. One is M54.5, which hasn't been billable since October 1, 2021; low back pain now uses M54.50, M54.51, or M54.59. The other is a symptom or Z code when a more specific diagnosis is documented.
What is the CPT code for a B12 injection?
A vitamin B12 injection bills as CPT 96372 for the administration plus J3420 (vitamin B12 cyanocobalamin, up to 1,000 mcg) for the drug. Medicare covers B12 injections only for documented indications in your MAC's coverage policy. First Coast's LCD L33967 and billing article A57755 are one example. Its covered codes include D51.0 to D51.9, E53.8, malabsorption codes (K90.x), and post-surgical malabsorption (K91.2). Fatigue alone usually isn't covered.
Does 96372 need an NDC?
The NDC goes on the drug line, never on 96372. Who requires it depends on the payer:
- Medicaid requires NDCs on physician-administered drug claims, a rule that dates to the Deficit Reduction Act of 2005.
- Medicare Part B fee-for-service generally doesn't require one on professional claims; First Coast says it's only needed for patients who are dually eligible for Medicaid.
- Medicare Advantage and commercial plans vary, and many require it.
- Unlisted drug codes such as J3490 need the drug name, dose, and NDC with almost every payer.
On a paper CMS-1500, the NDC goes in the shaded top part of item 24A: the N4 qualifier, the 11-digit NDC with no hyphens, a unit qualifier (UN, ML, GR, F2, or ME), and the quantity. Item 19 holds the name and dose of an unlisted drug. On an 837P, the NDC goes in loop 2410.
Billing GLP-1 injections with CPT 96372: Ozempic, Mounjaro, Wegovy, and Zepbound
There's no CPT code for Ozempic, Mounjaro, Wegovy, or Zepbound, because CPT codes describe services, not drugs. When a clinician gives a GLP-1 injection in the office and the payer covers in-office administration, the injection bills as 96372 and the drug goes on an unclassified code, J3490 (drugs) or J3590 (biologics) depending on the payer, with the NDC, drug name, and dose. Hospital outpatient departments typically use C9399.
Is there a J-code for Mounjaro or Ozempic? Not a dedicated one. Neither semaglutide nor tirzepatide had its own HCPCS code in the October 2026 update, so check the January 2027 HCPCS update before building templates.
Medicare works differently. These drugs are self-administered and filled at pharmacies, so they don't run through Part B or 96372. Ozempic and Mounjaro for type 2 diabetes are Part D drugs.
For weight loss, the Medicare GLP-1 Bridge gives eligible Part D enrollees access for $50 a month from July 1, 2026, through December 31, 2027. KFF Health News reports the covered drugs as Wegovy, the Zepbound KwikPen, and Foundayo, and says the $50 doesn't count toward the Part D deductible or out-of-pocket cap. CMS also delayed the Medicare Part D portion of the BALANCE model for 2027.
|
Drug |
Active ingredient |
In-office billing (where a commercial payer allows it) |
Medicare |
|---|---|---|---|
|
Ozempic |
Semaglutide |
96372 + J3490 or J3590 + NDC |
Part D (type 2 diabetes) |
|
Wegovy |
Semaglutide |
96372 + J3490 or J3590 + NDC |
Pharmacy, through the GLP-1 Bridge for weight loss |
|
Mounjaro |
Tirzepatide |
96372 + J3490 + NDC |
Part D (type 2 diabetes) |
|
Zepbound |
Tirzepatide |
96372 + J3490 + NDC |
Pharmacy, through the GLP-1 Bridge for weight loss (KwikPen) |
Prior authorization is the main denial driver here. Get it before the drug is given, and keep the approval number with the claim.
|
Get the GLP-1 approval before the injection, not after the denial Ozempic, Mounjaro and other high-cost drugs usually need prior authorization. If the approval is missing, the payer denies both the drug line and the 96372 line. Our prior authorization team requests and tracks each approval so the drug is cleared before your patient's appointment. |
Toradol (J1885) with CPT 96372
An IM ketorolac injection bills as 96372 plus J1885, which is per 15 mg: 30 mg is two units, and 60 mg is four. Does J1885 need a modifier? Not for its own sake. For Medicare, JW or JZ depends on the container: if the ketorolac came from a single-dose vial, the drug line needs JZ (nothing discarded) or JW (for the discarded amount). From a multi-dose vial, it takes neither.
How is a cholesterol injection billed in the office?
An in-office cholesterol injection of inclisiran (Leqvio) bills as CPT 96372 for the SC injection plus J1306 for the drug, and Medicare covers it under Part B. Self-injected PCSK9 inhibitors such as Repatha and Praluent are a different story. They appear on MAC self-administered drug exclusion lists, such as CGS's SAD article A52527, so they go through the pharmacy benefit with no 96372.
Top reasons CPT 96372 gets denied and how to fix them
Most 96372 denials fall into a few patterns, and the remittance codes point to the cause. The CARCs below are the ones payers commonly use; the exact code and remark code vary by payer and MAC.
|
What went wrong |
Common CARC |
Fix |
|---|---|---|
|
E/M billed without modifier 25, or 99211 billed with 96372 |
CO-97 (bundled) |
Add 25 to a qualifying 99212 to 99215 if the note supports it; drop 99211 |
|
Physician billed 96372 for a hospital outpatient or ED injection |
CO-58 (place of service) |
Bill the E/M only; the hospital reports the injection |
|
Diagnosis doesn't support the drug |
CO-50 (not medically necessary) or CO-11 (diagnosis inconsistent) |
Check the MAC's LCD or billing article and the documented diagnosis |
|
Missing or invalid NDC, units, or unlisted drug description |
CO-16 (missing information) |
Correct the drug line and resubmit |
|
No prior authorization |
CO-197 (authorization absent) |
Get authorization first; on future visits, check before the drug is ordered |
|
Units over the MUE |
CO-151 (frequency not supported) |
Check the MUE and its adjudication indicator; appeal with records if the MUE allows it |
Our guides to CO-97, CO-50, and CO-197 walk through each one in more detail.
The most common CPT 96372 approval issues and how to prevent them
In our experience, three problems account for most injection claim fixes. The first is modifier placement: 25 missing from the E/M, or 59 added to 96372 when it doesn't belong. The second is the drug line, with wrong units, a deleted J-code such as J1040, or a missing NDC for Medicaid. The third is authorization for high-cost drugs.
A short pre-submission check catches nearly all of these. Look at the modifier on each line, the units against the drug code's descriptor, the NDC for payers that need it, and the authorization number for any drug on the payer's list.
How to appeal a denied CPT 96372 claim
Start with the remittance. The CARC and RARC tell you whether the claim needs a correction or an appeal. Missing modifiers, units, and NDCs are corrections, so resubmit the fixed claim. Medical necessity and bundling disputes are appeals.
For Medicare, a redetermination request goes to the MAC within 120 days of receiving the initial determination (42 CFR 405.942). Send the visit note, the injection record (drug, dose, route, site, and who gave it), the order, and the authorization if one applied. Commercial appeal windows vary by contract and state.
|
Sitting on CO-97 or CO-16 injection denials? MedSole's denial management team works injection denials starting from the remittance. We correct and resubmit claims with modifier, unit and NDC errors, and we file Medicare redeterminations inside the 120-day window. |
How commercial payers handle 96372 differently
Medicare follows NCCI: 99211 isn't paid with 96372, modifier 25 goes on a separately identifiable E/M, and the physician doesn't bill 96372 in a facility setting. Medicaid programs also use NCCI edits and add the NDC requirement. Commercial payers can depart from those rules, and two published policies show how far.
BCBS Texas's CPCP026 policy doesn't pay 96372 separately when the same provider bills an E/M on the same date, asks for 59 on second and later injections, and wants a $0.00 drug line for patient-supplied drugs. Florida Blue's facility policy won't pay an injection billed with an E/M on a CMS-1500 at a facility place of service, even with a modifier. Check each payer's own policy before you build templates.
Frequently asked questions about CPT code 96372
What is the global period for CPT 96372?
CPT 96372 has an XXX global indicator in the Medicare Physician Fee Schedule, which means the global surgery rules don't apply to it. That's also why the 2027 same-day E/M reduction for 0-day global procedures shouldn't affect an E/M billed with 96372.
Can 99214 and 96372 be billed together?
Yes, for Medicare and NCCI-based payers. Bill 99214 with modifier 25 and 96372 without a modifier when the visit is significant and separately identifiable from giving the injection. Some commercial payers, such as BCBS Texas, don't pay 96372 separately with a same-day E/M, so check the payer's policy.
Can 99211 and 96372 be billed together?
Not for Medicare or payers that follow NCCI. 99211 isn't separately reportable with 96372, with or without modifier 25, because CMS valued the drug administration codes to include 99211's work. When a patient comes in only for an injection, bill 96372 and the drug code.
Can you bill 96372 with 2 units?
Yes, when two separate injections are given on the same day. Bill one unit of 96372 per injection with a drug line for each drug, check the current practitioner MUE, and follow the payer's format for multiple units. A single dose split across two syringes is still one injection.
Can 90471 and 96372 be billed together?
Yes, when a vaccine and a separate non-vaccine injection are given at the same visit. Report the vaccine administration code (90471, or G0008 to G0010 for those Medicare vaccines) and 96372, each with its product or drug code. Check the current NCCI PTP table before adding any modifier.
Is 96372 a CPT code or a HCPCS code?
Both. CPT 96372 is a Category I CPT code, and CPT codes make up HCPCS Level I, so "HCPCS 96372" refers to the same injection administration code. The drug given with it uses a HCPCS Level II code, such as J3420 or J1885.
What is the CPT code for Ozempic, Mounjaro, Wegovy, or Zepbound?
There isn't one, because CPT codes describe services, not drugs. When a commercial payer covers in-office administration, bill 96372 for the injection and J3490 or J3590 with the NDC for the drug. Medicare covers these through pharmacies: Part D for diabetes, and the GLP-1 Bridge for weight loss through December 31, 2027.
Does J1885 need a modifier?
Not on its own. J1885 (ketorolac, per 15 mg) is billed in units with 96372 for the IM injection. For Medicare, add JZ or JW only when the ketorolac came from a single-dose vial; a dose drawn from a multi-dose vial takes neither modifier.
Get help with injection billing
If injection claims keep coming back with modifier or NDC denials, the fix is usually a short checklist and a second set of eyes before submission. MedSole's outsourced medical billing services include pre-submission review of injection claims, with drug units, modifiers, and payer rules checked line by line.
This guide is educational and isn't legal or coding advice. Payer contracts, MAC policies, and the current CPT and HCPCS code sets control how a claim should be billed. CPT is a registered trademark of the American Medical Association.
Sources
- AMA: CPT code 96372; CPT 2027 code set release
- CMS: Medicare NCCI Policy Manual 2026, Chapter XI
- CMS: Proper use of modifiers 59, XE, XP, XS, XU (MLN1783722)
- CMS: NCCI PTP version 33.0, transmittal R13946CP; version 32.3, transmittal R13829CP
- CMS: CY 2027 Physician Fee Schedule final rule fact sheet
- CMS: CY 2026 PFS final rule summary, MLN MM14315
- CMS: Physician Fee Schedule look-up tool
- CMS: Discarded drugs and JW/JZ modifiers; JW/JZ FAQ
- CMS: Medicare Claims Processing Manual, Chapter 4
- CMS: Medicare GLP-1 Bridge announcement
- First Coast Service Options: Reporting the National Drug Code; LCD L33967 and article A57755, Vitamin B12 Injections
- Palmetto GBA: Billing article A59160
- CGS: Self-administered drug exclusion list, A52527
- Noridian: Initial drug administration guidance
- 42 CFR 405.942: Time frame for filing a redetermination
- BCBS Texas: Therapeutic, Prophylactic and Diagnostic Injection and Infusion policy (CPCP026)
- Florida Blue: Administration of Injections and Infusions in Facility Settings
- AHA News: CMS delays Part D portion of BALANCE model
- KFF Health News: Medicare GLP-1 Bridge coverage
- PayerPrice: CPT 96372 fee schedule estimates